Clinical efficacy of Probucol combined with Atorvastatin for patients with acute ischemic stroke

doi:10.3877/cma.j.issn.1674-0785.2021.04.003

Abstract

Abstract:

Objective

To investigate the clinical effectiveness of Probucol combined with Atorvastatin in patients with acute ischemic stroke and its influence on serum level of sLOX-1, Cyst-C, and hs-CRP.

Methods

A total of 126 patients with acute ischemic stroke admitted to Affiliated Hospital of Chengde Medical College from October 2018 to October 2019 were enrolled as the study subjects, and they were divided into either an observation group (n=63) or a control group (n=63). Both groups were given Atorvastatin on the basis of conventional treatment, and the observation group was additionally given Probucol. Blood lipid levels, atherosclerotic plaques, NIHSS, mRS, and MMSE scores, and the levels of sLOX-1, Cyst-C, and hs-CRP before and at 3 month after treatment were compared between the two groups. The levels of sLOX-1, Cyst-C, and hs-CRP were detected by ELSIA. Both groups were followed for 6 months, and the recurrence rate and adverse reactions were recorded.

Results

The total clinical effectiveness rate in the observation group was 93.65%, which was significantly higher than that of the control group (82.54%; P＜0.05). Compared with the values before treatment, triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), and apolipoprotein A (ApoA) in both groups were significantly decreased, while high density lipoprotein cholesterol (HDL-C) significantly increased after the treatment; the changes in the observation group were significantly better than those of the control group (P＜0.05). Compared with the values before treatment, the NIHSS and mRS scores in both groups were significantly reduced, MMSE score increased after the treatment, and the NIHSS and mRS scores were significantly lower, while MMSE score was higher in the observation group than in the control group (P＜0.05). After treatment, the carotid intima-media thickness, intimal plaque area, and the detection rate of vulnerable plaque were significantly reduced, and they were significantly lower in the observation group than in the control group (P＜0.05). The levels of sLOX-1, Cyst-C, and hs-CRP decreased significantly after treatment, and they were significantly lower in the observation group than in the control group (all P＜0.05). Compared with the control group (11.11%), the observation group (1.58%) had a significantly lower recurrence rate (P＜0.05). No severe adverse reactions occurred in either group.

Conclusion

Probucol combined with Atorvastatin can reduce blood lipid levels and inflammatory factors in patients with acute ischemic stroke, improve patients' neurological function, cognitive function, and quality of life, and reduce the rate of recurrence without significant adverse effects, which should be promoted in clinical practice.

Key words: Acute ischemic stroke, Soluble lectin-like oxidized low density lipoprotien receptor 1, Cystain C, High-sensitivity C-reactive protein, Atorvastatin, Probucol

Ning Yu, Chengbo Li, Min Li, Hairu Ji, Xiaoxuan Zhang. Clinical efficacy of Probucol combined with Atorvastatin for patients with acute ischemic stroke[J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(04): 249-254.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2021.04.003

https://zhlcyszz.cma-cmc.com.cn/EN/Y2021/V15/I04/249

Figures/Tables 5

组别	例数	基本痊愈（例）	显著进步（例）	进步（例）	无效（例）	死亡（例）	临床总有效［例（%）］
观察组	63	22	29	8	4	0	59（93.65）
对照组	63	16	20	16	10	1	52（82.54）
χ²值							4.582
P值							0.032

组别	例数	TG（mmol/L）	TC（mmol/L）	LDL-C（mmol/L）	HDL-C（mmol/L）	ApoA1（g/L）
观察组	63
治疗前		2.54±0.42	6.92±0.69	3.44±0.28	1.14±0.17	1.72±0.19
治疗后		1.02±0.17^ab	2.86±0.38^ab	1.68±0.25^ab	2.84±0.18^ab	1.11±0.04^ab
对照组	63
治疗前		2.50±0.39	6.88±0.86	3.31±0.63	1.01±0.33	1.69±0.37
治疗后		1.44±0.35^a	3.58±0.58^a	2.22±0.42^a	1.68±0.15^a	1.37±0.34^a

组别	例数	NIHSS	mRS	MMSE
观察组	63
治疗前		9.56±2.76	3.44±0.48	24.24±4.32
治疗后		4.58±2.03^ab	2.05±0.27^ab	28.18±1.36^ab
对照组	63
治疗前		10.17±2.98	3.38±0.66	24.37±4.14
治疗后		6.25±2.46^a	2.76±0.42^a	26.06±2.58^a

组别	例数	CAIMT（mm， $x ¯$ ±s）	内膜斑块面积（cm²， $x ¯$ ±s）	易损斑块［例（%）］
观察组	63
治疗前		1.65±0.29	1.18±0.02	32（50.79）
治疗后		1.09±0.17^ab	0.45±0.26^ab	16（25.40）^ab
对照组	63
治疗前		1.64±0.45	1.23±0.01	30（47.62）
治疗后		1.38±0.35^a	0.72±0.35^a	27（42.86）^a

组别	例数	CAIMT（mm， $x ¯$ ±s）	内膜斑块面积（cm²， $x ¯$ ±s）	易损斑块［例（%）］
观察组	63
治疗前		1.65±0.29	1.18±0.02	32（50.79）
治疗后		1.09±0.17^ab	0.45±0.26^ab	16（25.40）^ab
对照组	63
治疗前		1.64±0.45	1.23±0.01	30（47.62）
治疗后		1.38±0.35^a	0.72±0.35^a	27（42.86）^a

组别	例数	sLOX-1（ng/ml）	Cyst-C（mg/L）	hs-CPR（mg/dl）
观察组	63
治疗前		787.26±43.75	0.99±0.31	0.93±0.31
治疗后		309.88±34.85^ab	0.46±0.27^ab	0.52±0.03^ab
对照组	63
治疗前		784.37±45.38	0.92±0.17	0.91±0.27
治疗后		427.48±46.79^a	0.70±0.02^a	0.60±0.14^a

References 20

1	Al-Khaled M, Matthis C, Eggers J. Statin treatment in patients with acute ischemic stroke [J]. Im J Stroke, 2014, 9(5): 597-601.
2	Wang A, Yang Y, Su Z, et al. Association of oxidized low-density lipoprotein with prognosis of stroke and stroke subtypes [J]. Stroke, 2017, 48(1): 91-97.
3	Polidori MC, Frei B, Cherubini A, et al. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke [J]. Free Radic Biol Med, 1998, 25(4-5): 561-567.
4	张小庆. 阿托伐他汀联合普罗布考治疗动脉粥样硬化及预防脑卒中的临床效果评价 [J/OL]. 国际感染杂志(电子版), 2020, 9(1): 110-112.
5	Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association /American Stroke Association [J]. Stoke, 2018, 49(3): e46.
6	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018 [J]. 中华神经科杂志, 2018, 51(9): 666-682.
7	Clevert DA, Sommer WH, Zengel P, et al. Imaging of carotid arterial diseases with contrast-enhanced ultrasound (CEUS) [J]. Eur J Radiol, 2010, 80(1): 68-76.
8	吴逊. 全国第四届脑血管病学术会议纪要 [J]. 卒中与神经疾病, 1997(2): 51-55.
9	杨慧丽, 陈星宇, 郑维红. 氧化应激通过激活Cdk5抑制FOXO1的神经元损伤及其机制[J]. 西安交通大学学报(医学版), 2019, 40(3): 399-405.
10	Stack CA , Cole JW . Ischemic stroke in young adults [J]. Cur Opin in Cardio, 2018, 33(6): 594-604.
11	Rivard L, Khairy P, Talajic M, et al. Blinded randomized trial of anticoagulation to prevent ischemic stroke and neurocognitive impairment in AF (BRAIN-AF): methods and design [J]. Can J Cardio, 2019, 35(8):1069-1077.
12	张潇, 曾鼎华. 普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察 [J]. 中国药房, 2017, 28(5): 649-652.
13	张敏丽, 侯禹晨, 张大庆. 普罗布考对炎性单核细胞亚群分化的影响及可能机制 [J]. 中国动脉硬化杂志, 2017, 25(6): 548-552.
14	周远军, 杨道阔. 普罗布考联合通心络胶囊治疗急性脑梗死患者的近期预后及对IMT,ox-LDL的影响[J]. 中国社区医师, 2020, 36(7): 103-104.
15	黄宁涛. 普罗布考联合阿托伐他汀钙治疗急性缺血性脑卒中临床疗效观察 [J]. 淮海医药, 2018, 36(2): 144-146.
16	高巧营, 刘晋津, 吴腾, 等. 普罗布考联合山莨菪碱对糖尿病大鼠对比剂肾损伤的影响[J]. 山东医药, 2017, 57(46): 7-11.
17	蔡柳燕, 陈素芹, 张慧,等. 普罗布考联合阿托伐他汀对急性心肌梗死患者PCI术后左室重构,血脂的影响 [J]. 中国实用医刊, 2020, 47(2): 97-101.
18	Sawayama Y, Tatsukawa M, Kikuchi K, et al. Effect on carotid atherosclerosis of probucol plus levofloxacin for Chlamydia pneumoniae infection [J]. J Infect Chemother, 2007, 13(2): 92-98.
19	丛晓楠. 阿托伐他汀联合普罗布考治疗动脉粥样硬化及预防脑卒中的临床效果评价 [J]. 中国医药指南, 2020, 18(5):45-46.
20	庾建英, 付玉华, 张恩伟. 普罗布考联合阿托伐他汀对急性脑梗死的抗炎、降脂作用及神经功能的动态影响和预后观察 [J/OL]. 临床医药文献电子杂志, 2016, 3(21): 4284-4284, 4286.

[1]	Yuzhou Long, Hua Liu, Yunqian Zhang, Xingtong Li, Yunhu Fan, Zhengliang Shang, Zhenyu Song, Lihua Luo. Study on edaravone pretreatment prolonging thrombolytic time window by acute ischemic stroke and mechanism of ROS/TXNIP/NLRP3 pathway in rat [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(02): 65-74.
[2]	Jianhua Zhu, Qianqian Liu, Yulin Zheng, Shuibin Zhu. Effect of cerebral circulation therapy instrument combined with comprehensive rehabilitation training on the recovery period of acute ischemic stroke [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(06): 349-354.
[3]	Xiaohu Pan, Fayong Zhu, Hongyan Sun, Caiyun Yang, Yuezhou Cao, Sheng Liu. Efficacy of double stent-retriever thrombectomy in the treatment of refractory acute intracranial macrovascular occlusion at bifurcation [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(03): 171-177.
[4]	Wenjun Wu, Sha Sha, Cong Tian, Jian Zhu. Association between NLRP3 gene polymorphisms and inflammatory marks in elderly patients with acute myocardial infarction [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(03): 241-245.
[5]	Zhijia Xu, Zhenyu Jia, Linbo Zhao, Sheng Liu, Haibin Shi, Yuezhou Cao. Prognostic value of dynamic changes of high-sensitivity cardiac troponin T in acute ischemic stroke patients treated with endovascular thrombectomy in late time windows [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(01): 42-47.
[6]	Chendong Wang, Zhenyu Jia, Yuezhou Cao, Linbo Zhao, Sheng Liu, Haibin Shi. Correlation analysis of thrombus composition and clinical outcome in patients with acute ischemic stroke undergoing mechanical thrombectomy [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(04): 408-413.
[7]	Feng Lin, Hongyun Zhang, Yingkun He, Tianxiao Li. Perioperative NLR can predict the clinical prognosis of patients with acute anterior circulation large vessel occlusive stroke after thrombectomy [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(04): 396-403.
[8]	Xin Liang, Lanxiang Liu. Evaluation methods of leptomeningeal collateral circulation in patients with acute ischemic stroke [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 196-201.
[9]	Fuyuan Yao, Fanglan Chen, Zhe Deng. Risk factors for early neurological deterioration in non-thrombolysed patients with acute ischemic stroke [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2022, 08(04): 193-198.
[10]	Xingyun Yuan, Wanhong Chen, Liping Yu, Li Yao. Interventional treatment of vertebral artery occlusion with Wallenberg syndrome [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 394-399.
[11]	Xin Li, Yongkai Li, Shuqing Jiang, Xarbatgul·Samat, Jianzhong Yang. Risk factors related to hemorrhage transformation after intravenous thrombolysis in acute ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(04): 331-336.
[12]	Yun Zhang, Yuehong Pei, Yu Fu. Updates on intravenous thrombolytic therapy of acute ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(02): 83-88.
[13]	Xin Li, Jianzhong Yang. Research progress in risk factors of hemorrhage transformation after intravenous thrombolysis in acute ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(01): 9-15.
[14]	Xiaoli Zhang, Xin Han, Kunqi Han, Shanshan Li, Xiangjing Liu, Dongcheng Xu, Lei Mou. Risk factors related to prognosis of intravenous thrombolysis with alteplase in patients with acute cerebral infarction [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(05): 338-341.
[15]	Liao Wu, Ying Sun, Xiaoyu Ni, Guihua Ni. Short-term clinical efficacy of Edaravone Dexborneol for patients with acute anterior circulatory ischemic stroke [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(04): 253-257.

Please choose a citation manager

Content to export